Research programme: melanocyte modulators - IsoTis/University of Geneva

Drug Profile

Research programme: melanocyte modulators - IsoTis/University of Geneva

Latest Information Update: 06 Nov 2003

Price : $50

At a glance

  • Originator University of Geneva
  • Class
  • Mechanism of Action Melanocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperpigmentation

Most Recent Events

  • 06 Nov 2003 Discontinued - Preclinical for Hyperpigmentation in Switzerland (Topical)
  • 12 Dec 2002 Modex Therapeutics has merged with IsoTis NV to form IsoTis SA
  • 04 Oct 2001 Preclinical development for Hyperpigmentation in Switzerland (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top